$BRAXF News
Last published 4y ago
- 4y agoBRAXFBraxia Scientific Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug DevelopmentPR NewswireTORONTO, Jan. 31, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disor
- 4y agoBRAXFBraxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of PsilocybinPR NewswirePatients receive first dose in first-ever Health Canada-approved, multi-dose psilocybin clinical trial conducted at Braxia Scientific's subsidiary CRTCE clinic Trial establishes psilocybin treatment framework for patients with TRD and opens new pathwa
- 4y agoBRAXFBraxia Scientific Reports Second Quarter 2022 Financial Results and Provides Corporate UpdatePR NewswireExpanded clinical infrastructure to support a growing portfolio of clinical trials of novel interventions and for drug discovery; 14 registered clinical trials in depression, led by Company CEO and Chief Medical and Scientific Officer, completed or
- 5y agoBRAXFBraxia Scientific CEO Dr. Roger McIntyre to Join Advisory Board of At-Home Telemedicine Platform KetaMDPR NewswireTORONTO, Nov. 9, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related diso
- 5y agoBRAXFBraxia Scientific CEO Dr. Roger McIntyre to Deliver Keynote Address at Wonderland: MiamiPR NewswireTORONTO, Nov. 8, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorde
- 5y agoBRAXFBraxia Scientific Graduates First Cohort of Medical Professionals from Psilocybin-Assisted Therapy Training Program; Ready to Start Health Canada Approved Psilocybin Clinical TrialPR NewswireTORONTO, Nov. 2, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disord
- 5y agoBRAXFBraxia Scientific Announces Voting Results from the Annual General Meeting of ShareholdersPR NewswireTORONTO, Oct. 29, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disor
- 5y agoBRAXFBraxia Scientific Provides New Audio Webcast and Dial-In Number for Annual General MeetingPR NewswireTORONTO, Oct. 27, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and re
- 5y agoBRAXFBraxia Scientific Featured in National News, W5 Canada's Most-Watched Documentary Series, Providing Access and Promoting Use of Ketamine to Treat Brain-Based IllnessesPR NewswireTORONTO, Oct. 22, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disor
- 5y agoBRAXFJournal of the Royal Society of Medicine Publishes New COVID-19 Suicide Research Led by Braxia Scientific CEO Dr. Roger McIntyrePR NewswireFindings Underscore Company Core Objectives to Develop Ketamine Derivatives as Additional Measures to Further Reduce Suicidality TORONTO, Oct. 21, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB
- 5y agoBRAXFBraxia Scientific CEO Dr. Roger McIntyre to Share Stage With NBA Champion Lamar Odom and 'Psychedelic Concierge' Zappy Zapolin to Discuss the Benefits of Ketamine Treatment for Mental HealthPR NewswirePanel discussion on November 9 at Wonderland: Miami will review the benefits of ketamine treatment for depression and other mental health conditions TORONTO, Oct. 14, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BR
- 5y agoBRAXFBraxia Scientific Reports Encouraging Results of Ketamine Study Showing Significant Reduction in Depressive Symptoms and Suicidality with Ketamine as a Solo TreatmentPR NewswireTORONTO, Sept. 30, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related diso
- 5y agoBRAXFBraxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient BasePR NewswireRevenue from four Canadian clinics increased 80.3% to $407,075 year-over-year Exceeding monthly IV Ketamine infusion targets, ramping up infusions at new Montreal clinic Advancing three funded clinical trials through Braxia Scientific's network of c
- 5y agoBRAXFBraxia Scientific to Commence Landmark Clinical Trial to Conduct Canada's First Multiple-Dose Psilocybin Clinical Trial for Treatment Resistant DepressionPR NewswireFirst multiple-dose psilocybin clinical trial will be conducted at Braxia Health's Canadian Rapid Treatment Centers Trial will include adults with treatment-resistant depression and will also enroll adults who have previously tried electroconvulsive t
- 5y agoBRAXFBraxia Scientific Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021PR NewswireTORONTO, Aug. 17, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and rel
- 5y agoBRAXFBraxia Scientific Announces Participation at Canaccord Genuity 2021 Annual Growth Conference August 10-12PR NewswireTORONTO, Aug. 6, 2021 /CNW Telbec/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related d
- 5y agoBRAXFBraxia Scientific Provides Corporate Update and Reports Fiscal Fourth Quarter and Full-Year 2021 Financial ResultsPR NewswireTORONTO, July 30, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), today announced the filing of its fiscal fourth-quarter and year-end results for the three- and 12-month periods ending March
- 5y agoBRAXFBraxia Scientific CEO, Chief Medical Officer Awarded $918,000 by Canadian Government to Study Benefits of Integrating Ketamine with Cognitive Behavioural Therapy to Reduce SuicidalityPR NewswireInnovative Ketamine clinical trial ranked in the 94th percentile by the CIHR peer review committee Suicidality remains second-leading cause of death among youth and young adults, and the 9th most common cause of death among Canadians TORONTO, July
- 5y agoARECAURQFAZASFBIOC+22Proactive news headlines including American Resources, Nextleaf Solutions, Versus Systems and Vox RoyaltyGlobeNewswireNew York , July 20, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Arizona Silver Exploration Inc (CVE:AZS) (OTC:AZASF) h
- 5y agoBRAXFBraxia Scientific Secures Approval for Direct Billing Insurance on Ketamine Treatments for Veterans Affairs Canada ClientsPR NewswireTORONTO, July 20, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disord
- 5y agoBRAXFBraxia Scientific to Discuss Psychiatric Treatment Discovery and Development with Oxford University Researchers at AIMday Experimental Medicine in Psychiatry on July 7, 2021PR NewswireTORONTO, July 7, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research and development company along with clinics providing innovative ketamine treatments for persons with depress
- 5y agoBRAXFBraxia Scientific Announces Participation at PSYCH Investor Summit on July 7, 2021PR NewswireTORONTO, July 6, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorde
- 5y agoAMYZFBABYFBLGOBNVIF+18Proactive news headlines including Alternus Energy, Nomad Royalty, authID.ai, Biolargo and TechX TechnologiesGlobeNewswireNew York , June 29, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Nomad Royalty Company Ltd (TSE:NSR) (OTCQX:NSRXF) (FRA
- 5y agoBRAXFBraxia Scientific Launches Psilocybin-Assisted Clinical Therapy Training Program to Develop New Generation of Qualified Physicians, Psychotherapists and Psychologists for Mental HealthPR NewswireTORONTO, June 29, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders,
- 5y agoBRAXF/R E P E A T -- Braxia Scientific Awarded Government of Canada Funding to Complete First of its Kind Ketamine Clinical Trial for Bipolar Depression/PR NewswireFully funded by the Canadian Institute of Health Research (CIHR), this multi-site clinical trial will take place at Toronto's University Health Network (UHN) and Braxia's CRTCE Research Clinic Largest study of its kind with IV Ketamine to be conducted
- 5y agoABMLAGNPFAPEUFBRAXF+16Proactive news headlines including GreenBank Capital, Lucky Minerals, Braxia Scientific and Exro TechnologiesGlobeNewswireNew York , June 17, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies: Pacific Empire Minerals Corp (CVE:PEMC) (OTCQB:PEMSF) expands
- 5y agoBRAXFBraxia Scientific Awarded Government of Canada Funding to Complete First of its Kind Ketamine Clinical Trial for Bipolar DepressionPR NewswireFully funded by the Canadian Institute of Health Research (CIHR), this multi-site clinical trial will take place at Toronto's University Health Network (UHN) and Braxia's CRTCE Research Clinic Largest study of its kind with IV Ketamine to be conducted
- 5y agoBRAXF/R E P E A T -- Braxia Scientific to Present at the Psychedelics in Psychiatry and Beyond Virtual Conference Hosted by H.C. Wainwright & Co. on June 17, 2021/PR NewswireTORONTO, June 16, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disord
- 5y agoBRAXFBraxia Scientific to Present at the Psychedelics in Psychiatry and Beyond Virtual Conference Hosted by H.C. Wainwright & Co. on June 17, 2021PR NewswireTORONTO, June 16, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disord
- 5y agoALPPAMYZFAQSZFASDRF+16Proactive news headlines including Marble Financial, Vuzix Corp, Talon Metals and UnigoldGlobeNewswireNew York, June 09, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Vuzix Corporation (NASDAQ:VUZI) rises to the ranks of the
- 5y agoBRAXFAmerican Journal of Psychiatry Publishes International Ketamine and Esketamine Treatment Guidance Led by Braxia Scientific CEO Dr. Roger McintyrePR NewswireInternational Expert Opinion and Implementation Guidance outlines Ketamine and Esketamine treatment parameters setting the standard for the clinical implementation of these rapid-acting treatments in treatment resistant depression Guidance published i
- 5y agoBRAXFBraxia Scientific Appoints Dr. David Greenberg to Board of DirectorsPR NewswireTORONTO, May 31, 2021 /PRNewswire/ - Braxia Scientific Corp. (the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 496), a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders